欧洲带状疱疹管理共识指南(S2k)第二部分:治疗
该指南由欧洲皮肤病论坛与欧洲皮肤病与性病学会合作制定,采用AGREE II标准结构化流程,由皮肤科、病毒学、眼科等多学科专家对带状疱疹治疗(抗病毒药物、疼痛管理、局部治疗)进行系统评估并正式共识推荐,旨在改善疾病病程、急性疼痛和生活质量,减少带状疱疹后神经痛等并发症。
要点
- 指南对带状疱疹的抗病毒药物、疼痛管理和局部治疗给出正式共识推荐。
- 推荐需结合不同临床情境及各国监管、可及性和报销等法律背景审慎应用。
- 目标是缩短病程、减轻急性疼痛、改善生活质量并减少带状疱疹后神经痛。
核心结论
- 该指南为带状疱疹患者治疗提供基于共识的推荐,涵盖抗病毒药物、疼痛管理和局部治疗。
研究设计与样本
- 指南制定遵循结构化预定义流程并参考AGREE II质量标准,由dEBM负责规划组织。
- 专家组由皮肤科、病毒学/感染科、眼科、耳鼻喉科、神经科和麻醉科专家组成。
- 推荐经共识会议正式同意,并经内部和外部广泛审查后由委托学会批准。
主要发现
- 指南第二部分评估了带状疱疹的治疗干预,包括抗病毒药物、疼痛管理和局部治疗。
关键数值与推荐
- 专家小组针对不同临床情境正式共识了带状疱疹治疗推荐。
- 使用者需仔细核查推荐是否适合预期应用背景。
- 国际指南背景下需考虑各国在监管批准、可及性和报销方面的差异。
临床怎么用
- 临床可依据该共识推荐选择抗病毒药物、疼痛管理和局部治疗方案。
- 应用推荐时应结合患者人群、皮损定位及本国监管与报销条件。
局限性
- 国际指南需考虑各国监管批准、可及性和报销等法律背景差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Herpes zoster (HZ, shingles) is a frequent medical condition which may severely impact the quality of life of affected patients. Different therapeutic approaches to treat acute HZ are available. The aim of this European project was the elaboration of a consensus-based guideline on the management of patients who present with HZ, considering different patient populations and different localizations. This interdisciplinary guideline aims at an improvement of the outcomes of the acute HZ management concerning disease duration, acute pain and quality of life of the affected patients and at a reduction in the incidence of postherpetic neuralgia (PHN) and other complications. The guideline development followed a structured and pre-defined process, considering the quality criteria for guidelines development as suggested by the AGREE II instrument. The steering group was responsible for the planning and the organization of the guideline development process (Division of Evidence-Based Medicine, dEBM). The expert panel was nominated by virtue of clinical expertise and/or scientific experience and included experts from the fields of dermatology, virology/infectiology, ophthalmology, otolaryngology, neurology and anaesthesiology. Recommendations for clinical practice were formally consented during the consensus conference, explicitly considering different relevant aspects. The guideline was approved by the commissioning societies after an extensive internal and external review process. In this second part of the guideline, therapeutic interventions have been evaluated. The expert panel formally consented recommendations for the treatment of patients with HZ (antiviral medication, pain management, local therapy), considering various clinical situations. Users of the guideline must carefully check whether the recommendations are appropriate for the context of intended application. In the setting of an international guideline, it is generally important to consider different national approaches and legal circumstances with regard to the regulatory approval, availability and reimbursement of diagnostic and therapeutic interventions.
引用
- Werner RN, Nikkels AF, Marinović B, et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol. 2016. PMID: 27579792. doi:10.1111/jdv.13957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。